Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01720610-201108000-00011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Thromboembolic events associated with combined oral contraceptives: a real-world study based on the FDA adverse event reporting system (FAERS) database.
Expert Opin Drug Saf
December 2024
Department of Pharmacy, Yunnan Maternal and Child Health Hospital, Kunming, China.
Background: The clinical characteristics and time-to-onset of thromboembolic events (TEEs) associated with combined oral contraceptives (COCs) remain unclear, our current study was committed to providing more data for risk evaluation and management of COCs treatment.
Research Design And Methods: This pharmacovigilance study was conducted in the FAERS database. We evaluated significant pharmacovigilance signals by using disproportionality analysis.
The benefits of estetrol addition to drospirenone for contraception.
AJOG Glob Rep
November 2023
Department of Obstetrics and Gynecology, University of Liège, Liège, Belgium (Prof Foidart and Prof Gaspard).
Ethinylestradiol and drospirenone combined oral contraceptive formulations have been marketed for >20 years. Drospirenone has antimineralocorticoid and anti-androgenic effects that may offer several health benefits. Recently, 2 new drospirenone-containing oral contraceptives entered the market, 1 as a progestin-only pill containing 4 mg drospirenone and the other as a combined oral contraceptive containing 15 mg estetrol and 3 mg drospirenone.
View Article and Find Full Text PDFCombined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk.
Front Endocrinol (Lausanne)
February 2022
Research Department, Qualiblood s.a., Namur, Belgium.
Many factors must be considered and discussed with women when initiating a contraceptive method and the risk of venous thromboembolism (VTE) is one of them. In this review, we discuss the numerous strategies that have been implemented to reduce the thrombotic risk associated with combined oral contraceptives (COCs) from their arrival on the market until today. Evidences suggesting that COCs were associated with an increased risk of VTE appeared rapidly after their marketing.
View Article and Find Full Text PDFSignal detection of drospirenone-containing oral contraceptives: a disproportionality analysis using the Korea Adverse Event Reporting System Database, 2008-2017.
BMJ Open
August 2021
School of Pharmacy, Sungkyunkwan University, Suwon, Korea (the Republic of)
Objectives: To detect the signals for drospirenone-containing oral contraceptives (DCOCs) and describe the reporting pattern of adverse events (AEs) caused by DCOCs compared with levonorgestrel/desogestrel/gestodene-containing (second/third generation) oral contraceptives.
Design: A descriptive analysis of claims data.
Setting: The Korea Institute of Drug Safety & Risk Management-Korea Adverse Event Reporting System Database from 1 February 2008 to 31 December 2017.
Drospirenone-containing oral contraceptives do not affect glucose regulation and circulating corticosterone.
J Basic Clin Physiol Pharmacol
August 2019
Department of Physiology, College of Health Sciences, University of Ilorin, PMB 1515, Ilorin 240003, Nigeria, Phone: +2348035755360.
Background Combined oral contraceptive (COC) use has been associated with an increased risk of insulin resistance (IR) and other adverse cardiovascular events, despite efforts to reduce the dosage and/or progestin type. COC containing drospirenone (DRSP) is an analog of spironolactone, hence its antimineralocorticoid and antiandrogenic characteristics have been deemed beneficial, although the benefits and/or negative outcome of its usage have not been fully elucidated. We therefore hypothesized that COC with DRSP component will not affect glucose regulation and circulating corticosterone.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!